PMID- 33251670
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210922
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 22
IP  - 12
DP  - 2020 Dec
TI  - Baseline characteristics of patients with heart failure with preserved ejection 
      fraction in the EMPEROR-Preserved trial.
PG  - 2383-2392
LID - 10.1002/ejhf.2064 [doi]
AB  - AIMS: EMPEROR-Preserved is an ongoing trial evaluating the effect of 
      empagliflozin in patients with heart failure with preserved ejection fraction 
      (HFpEF). This report describes the baseline characteristics of the 
      EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF 
      trials. METHODS AND RESULTS: EMPEROR-Preserved is a phase III randomized, 
      international, double-blind, parallel-group, placebo-controlled trial in which 
      5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] 
      with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients 
      were required to have elevated N-terminal pro B-type natriuretic peptide 
      (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in 
      patients with atrial fibrillation) along with evidence of structural changes in 
      the heart or documented history of heart failure hospitalization. Among patients 
      enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North 
      America), the mean age was 72 +/- 9 years, 45% were women. Almost all patients had 
      New York Heart Association class II or III symptoms (99.6%), and 23% had prior 
      heart failure hospitalization within 12 months. Thirty-three percent of the 
      patients had baseline LVEF of 41-50%. The mean LVEF (54 +/- 9%) was slightly lower 
      while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with 
      previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and 
      chronic kidney disease (50%) were common. The majority of the patients were on 
      angiotensin-converting enzyme inhibitors/angiotensin receptor 
      blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers 
      (86%), and 37% of patients were on mineralocorticoid receptor antagonists. 
      CONCLUSION: When compared with prior trials in HFpEF, the EMPEROR-Preserved 
      cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median 
      NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. 
      Results of the EMPEROR-Preserved trial will be available in 2021.
CI  - (c) 2020 The Authors. European Journal of Heart Failure published by John Wiley & 
      Sons Ltd on behalf of European Society of Cardiology.
FAU - Anker, Stefan D
AU  - Anker SD
AD  - Department of Cardiology (CVK), Berlin Institute of Health Center for 
      Regenerative Therapies (BCRT), Berlin, Germany.
AD  - German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Berlin, 
      Germany.
AD  - Charite Universitatsmedizin Berlin, Berlin, Germany.
FAU - Butler, Javed
AU  - Butler J
AD  - University of Mississippi School of Medicine, Jackson, MI, USA.
FAU - Filippatos, Gerasimos
AU  - Filippatos G
AD  - National and Kapodistrian University of Athens School of Medicine, Athens, 
      Greece.
FAU - Shahzeb Khan, Muhammad
AU  - Shahzeb Khan M
AD  - University of Mississippi School of Medicine, Jackson, MI, USA.
FAU - Ferreira, Joao Pedro
AU  - Ferreira JP
AD  - Universite de Lorraine, Inserm INI-CRCT, Nancy, France.
FAU - Bocchi, Edimar
AU  - Bocchi E
AD  - Sao Paulo University Medical School, Sao Paulo, Brazil.
FAU - Bohm, Michael
AU  - Bohm M
AD  - Universitatsklinikum des Saarlandes und Medizinische Fakultat der Universitat des 
      Saarlandes, Homberg, Germany.
FAU - Brunner-La Rocca, Hans Pieter
AU  - Brunner-La Rocca HP
AD  - Maastricht University Medical Center, Maastricht, The Netherlands.
FAU - Choi, Dong-Ju
AU  - Choi DJ
AD  - Seoul National University Bundang Hospital, Seoul, Republic of Korea.
FAU - Chopra, Vijay
AU  - Chopra V
AD  - Medanta Medicity to Max Superspeciality Hospital, Saket, New Delhi, India.
FAU - Chuquiure, Eduardo
AU  - Chuquiure E
AD  - Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico, Mexico.
FAU - Giannetti, Nadia
AU  - Giannetti N
AD  - Centre Universitaire de Sante McGill, Montreal, QC, Canada.
FAU - Gomez-Mesa, Juan Esteban
AU  - Gomez-Mesa JE
AD  - Fundacion Valle del Lili, Cali, Colombia.
FAU - Janssens, Stefan
AU  - Janssens S
AD  - University Hospitals Leuven, Belgium, Brazil.
FAU - Januzzi, James L
AU  - Januzzi JL
AD  - Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
FAU - Gonzalez-Juanatey, Jose R
AU  - Gonzalez-Juanatey JR
AD  - Complejo Hospitalario Universitario de Santiago, CIBERCV, A Coruna, Spain.
FAU - Merkely, Bela
AU  - Merkely B
AD  - Semmelweis University, Budapest, Hungary.
FAU - Nicholls, Stephen J
AU  - Nicholls SJ
AD  - Victorian Heart Institute, Monash University, Clayton, VIC, Australia.
FAU - Perrone, Sergio V
AU  - Perrone SV
AD  - Department of Cardiology, FLENI Institute, Buenos Aires, Argentina.
FAU - Pina, Ileana L
AU  - Pina IL
AD  - Wayne State University, Detroit, MI, USA.
FAU - Ponikowski, Piotr
AU  - Ponikowski P
AD  - Wroclaw Medical University, Wroclaw, Poland.
FAU - Senni, Michele
AU  - Senni M
AD  - ASST Papa Giovanni XXIII, Bergamo, Italy.
FAU - Seronde, Marie-France
AU  - Seronde MF
AD  - Centre Hospitalier Regional et Universitaire de Besancon, Besancon, France.
FAU - Sim, David
AU  - Sim D
AD  - National Heart Centre, Singapore.
FAU - Spinar, Jindrich
AU  - Spinar J
AD  - University Hospital, Masaryk University Hospital, Brno, Czech Republic.
FAU - Squire, Iain
AU  - Squire I
AD  - NIHR Cardiovascular Biomedical Research Centre, Glenfield Hospital, Leicester, 
      UK.
FAU - Taddei, Stefano
AU  - Taddei S
AD  - Department of Clinical and Experimental Medicine, University of Pisa, Pisa, 
      Italy.
FAU - Tsutsui, Hiroyuki
AU  - Tsutsui H
AD  - Kyushu University, Fukuoka City, Japan.
FAU - Verma, Subodh
AU  - Verma S
AD  - St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
FAU - Vinereanu, Dragos
AU  - Vinereanu D
AD  - University of Medicine and Pharmacy Carol Davila, University and Emergency 
      Hospital, Bucharest, Romania.
FAU - Zhang, Jian
AU  - Zhang J
AD  - Fuwai Hospital Chinese Academic of Medical Science, Beijing, China.
FAU - Jamal, Waheed
AU  - Jamal W
AD  - Boehringer Ingelheim International GmbH, Ingelheim, Germany.
FAU - Schnaidt, Sven
AU  - Schnaidt S
AD  - Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
FAU - Schnee, Janet M
AU  - Schnee JM
AD  - Boehringer Ingelheim Pharma, Inc., Ridgefield, CT, USA.
FAU - Brueckmann, Martina
AU  - Brueckmann M
AD  - Boehringer Ingelheim International GmbH, Ingelheim, Germany.
AD  - Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
FAU - Pocock, Stuart J
AU  - Pocock SJ
AD  - Department of Medical Statistics, London School of Hygiene & Tropical Medicine, 
      London, UK.
FAU - Zannad, Faiez
AU  - Zannad F
AD  - Universite de Lorraine, Inserm INI-CRCT, Nancy, France.
FAU - Packer, Milton
AU  - Packer M
AD  - Baylor University Medical Center, Dallas, TX, USA.
AD  - Imperial College, London, UK.
CN  - EMPEROR-Preserved Trial Committees and Investigators
LA  - eng
GR  - Boehringer Ingelheim/
GR  - Eli Lilly and Company/
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Biomarkers)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Glucosides)
RN  - 0 (Peptide Fragments)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
CIN - Eur J Heart Fail. 2021 May;23(5):841. PMID: 33377246
CIN - Eur J Heart Fail. 2021 Aug;23(8):1256-1259. PMID: 33502794
MH  - Aged
MH  - Aged, 80 and over
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Biomarkers/blood
MH  - Cardiovascular Agents/*therapeutic use
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Glucosides/*therapeutic use
MH  - *Heart Failure/blood/diagnosis/drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Stroke Volume
OTO - NOTNLM
OT  - Empagliflozin
OT  - Heart failure with preserved ejection fraction
OT  - Sodium-glucose co-transporter 2 inhibitors
EDAT- 2020/12/01 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/30 05:58
PHST- 2020/11/02 00:00 [received]
PHST- 2020/11/22 00:00 [revised]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
PHST- 2020/11/30 05:58 [entrez]
AID - 10.1002/ejhf.2064 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2020 Dec;22(12):2383-2392. doi: 10.1002/ejhf.2064.